drugset / Trial / NCT01896700
Methylphenidate to Improve Balance and Walking in MS
Phase 2/3
Completed
24 enrolled
Oregon Health and Science University
Portland VA Medical Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy. It is also often prescribed off label to people with MS to improve fatigue. It is proposed that methylphenidate may also improve imbalance and walking deficits in MS by improving concentration and central integration, one of the primary mechanisms thought to underlie imbalance and walking deficits in MS.
Timeline
- Start
- 2013-07
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylphenidate | Small molecule | 60 mg | Oral |